【美股焦點】FDA批准Biogen阿茲海默症藥物 相關生物科技股炒起 – 香港經濟日報 – 即時新聞頻道 – iMoney智富 – 股樓投資 2021-06-08T10:28:15-04:00June 8th, 2021| share this article! 本周一美國食品及藥物管理局批准美國藥廠Biogen(US:BIIB)研發的阿茲海默症藥物「Aduhelm」,是獲得FDA批准的第一款減緩相關症狀的藥物。據悉Aduhelm全年劑量定價為5.6萬美元,公 Read More share this article! Related Posts Chinese Vice-Premier calls on cities to buy back residential land, unsold homes May 17th, 2024 Temasek’s venture capital arm to launch first Japan-focused fund May 17th, 2024 China’s home prices extend fall in April before Beijing’s rescue plans May 17th, 2024 Hong Kong must take a holistic approach to develop green hydrogen: think tank May 17th, 2024